Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30916078 | 0.93 | AAK1 (0.36) | AAK1MMP13CA14CTSKCA1 | |
| SCHEMBL30916082 | 0.91 | AAK1 (0.35) | AAK1MMP13CA14CTSKCA1 | |
| SCHEMBL21447817 | 0.87 | AAK1 (0.35) | AAK1MMP13CA14CA1CA2 | |
| SCHEMBL30916093 | 0.86 | AAK1 (0.33) | AAK1MMP13CA14CTSK | |
| SCHEMBL18248194 | 0.85 | AAK1 (0.36) | AAK1MMP13CA14CTSKCA1 | |
| SCHEMBL18248195 | 0.85 | AAK1 (0.36) | AAK1MMP13CA14CTSKCA1 | |
| SCHEMBL19245050 | 0.85 | MMP13 (0.36) | AAK1MMP13CA14CTSK | |
| SCHEMBL20309981 | 0.83 | CA1 (0.40) | AAK1MMP13CA14CTSKCA1 | |
| SCHEMBL30916053 | 0.82 | AAK1 (0.41) | AAK1MMP13 | |
| SCHEMBL7333433 | 0.82 | AAK1 (0.41) | AAK1MMP13CA14CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | AAK1 3150/4885MMP13 434/4885CA14 1962/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | AAK1 3436/4885MMP13 440/4885CA14 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.